WHO monographs on selected medicinal plants - travolekar.ru
WHO monographs on selected medicinal plants - travolekar.ru WHO monographs on selected medicinal plants - travolekar.ru
Cortex Magnoliae Contraindications Hypersensitivity or allergy to the plant material. Warnings No information was found. Precautions General No information was found. Drug interactions None reported. Drug and laboratory test interactions None reported. Carcinogenesis, mutagenesis, impairment of fertility An aqueous extract of the bark was not mutagenic in the Ames test in Salmonella typhimurium strains TA98 and TA100 at concentrations up to 40.0 mg per agar plate (41). Magnolol at concentrations of 10 -9 and 10 -7 M reduced ferrous sulfate-induced lipid peroxidation and reduction in sperm motility and protected sperm from lipid peroxidation in vitro (42). Pregnancy: teratogenic effects None reported. Pregnancy: non-teratogenic effects Due to a lack of safety data the use of the crude drug during pregnancy is not recommended. Nursing mothers Due to a lack of safety data the use of the crude drug during breastfeeding is not recommended. Paediatric use Due to a lack of safety data the use of the crude drug in children under the age of 12 years is not recommended. Adverse reactions No information was found. 175
- Page 132 and 133: WHO monogr
- Page 134 and 135: WHO monogr
- Page 136 and 137: WHO monogr
- Page 138 and 139: WHO monogr
- Page 140 and 141: WHO monogr
- Page 142 and 143: WHO monogr
- Page 144 and 145: WHO monogr
- Page 146 and 147: WHO monogr
- Page 148 and 149: Lichen Islandicus Definition Lichen
- Page 150 and 151: WHO monogr
- Page 152 and 153: WHO monogr
- Page 154 and 155: WHO monogr
- Page 156 and 157: WHO monogr
- Page 158 and 159: WHO monogr
- Page 160 and 161: WHO monogr
- Page 162 and 163: WHO monogr
- Page 164 and 165: WHO monogr
- Page 166 and 167: WHO monogr
- Page 168 and 169: WHO monogr
- Page 170 and 171: WHO monogr
- Page 172 and 173: WHO monogr
- Page 174 and 175: WHO monogr
- Page 176 and 177: WHO monogr
- Page 178 and 179: WHO monogr
- Page 180 and 181: WHO monogr
- Page 184 and 185: WHO monogr
- Page 186 and 187: WHO monogr
- Page 188 and 189: WHO monogr
- Page 190 and 191: WHO monogr
- Page 192 and 193: WHO monogr
- Page 194 and 195: WHO monogr
- Page 196 and 197: WHO monogr
- Page 198 and 199: WHO monogr
- Page 200 and 201: Fructus Momordicae Definition Fruct
- Page 202 and 203: WHO monogr
- Page 204 and 205: WHO monogr
- Page 206 and 207: WHO monogr
- Page 208 and 209: WHO monogr
- Page 210 and 211: WHO monogr
- Page 212 and 213: WHO monogr
- Page 214 and 215: WHO monogr
- Page 216 and 217: WHO monogr
- Page 218 and 219: Fructus Myrtilli Definition Fructus
- Page 220 and 221: WHO monogr
- Page 222 and 223: WHO monogr
- Page 224 and 225: WHO monogr
- Page 226 and 227: WHO monogr
- Page 228 and 229: WHO monogr
- Page 230 and 231: WHO monogr
<str<strong>on</strong>g>WHO</str<strong>on</strong>g> <str<strong>on</strong>g>m<strong>on</strong>ographs</str<strong>on</strong>g> <strong>on</strong> <strong>selected</strong> <strong>medicinal</strong> <strong>plants</strong><br />
decreased cor<strong>on</strong>ary vascular resistance in a dose-dependent manner<br />
(p < 0.01) (34). Magnolol (c<strong>on</strong>centrati<strong>on</strong> 10–100 μg/ml) inhibited norepinephrine-induced<br />
phasic and t<strong>on</strong>ic c<strong>on</strong>tracti<strong>on</strong>s in rat thoracic aorta in<br />
vitro (35).<br />
Miscellaneous activities<br />
H<strong>on</strong>okiol and magnolol increase choline acetyl-transferase activity, inhibit<br />
acetylcholinesterase, promote potassium-induced acetylcholine release<br />
and exhibit neurotrophic functi<strong>on</strong> in vitro. In c<strong>on</strong>scious, freelymoving<br />
rats a dose of h<strong>on</strong>okiol or magnolol (10 -4 –10 -6 M) was perfused<br />
into the hippocampus via a dialysis probe. The results showed that at a<br />
dose of 10 -4 M h<strong>on</strong>okiol or magnolol markedly increased extracellular<br />
acetylcholine release to 165.5% and 237.83% of the basal level, respectively.<br />
However, lower c<strong>on</strong>centrati<strong>on</strong>s of either compound failed to elicit<br />
significant acetylcholine release (36).<br />
The effects of magnolol <strong>on</strong> thermoregulati<strong>on</strong> and hypothalamic release<br />
of 5-hydroxytryptamine were assessed in normothermic rats and in febrile<br />
rats treated with interleukin-1 beta. Intraperit<strong>on</strong>eal administrati<strong>on</strong> of magnolol<br />
(25.0–100.0 mg/kg bw) produced a decrease in col<strong>on</strong> temperature, an<br />
increase in foot skin temperature, a decrease in metabolic rate and a decrease<br />
in the endogenous release of 5-hydroxytryptamine in the rat hypothalamus.<br />
Depleti<strong>on</strong> of 5-hydroxytryptamine in rat brain, produced by<br />
intracerebroventricular pretreatment with 5,7-dihydroxytryptamine, attenuated<br />
the magnolol-induced hypothermia and cutaneous vasodilati<strong>on</strong>,<br />
and decreased metabolism (37).<br />
Muscle relaxati<strong>on</strong> effects<br />
Intraperit<strong>on</strong>eal administrati<strong>on</strong> of an ether extract of the c<strong>ru</strong>de d<strong>ru</strong>g, at a<br />
dose of 1.0 g/kg bw induced a loss of the righting reflex 30 minutes after<br />
injecti<strong>on</strong>. In mice, intraperit<strong>on</strong>eal administrati<strong>on</strong> of magnolol (50.0–<br />
500.0 mg/kg bw) produced sedati<strong>on</strong>, ataxia, muscle relaxati<strong>on</strong> and a loss<br />
of righting reflex. Intraperit<strong>on</strong>eal administrati<strong>on</strong> of magnolol and h<strong>on</strong>okiol<br />
(50.0 mg/kg bw) to young chicks suppressed spinal reflexes (38–40).<br />
Toxicity<br />
The median lethal dose after intraperit<strong>on</strong>eal injecti<strong>on</strong> of a decocti<strong>on</strong> is<br />
6 g/kg bw in mice, and the median lethal dose is 4.25 g/kg bw in cats after<br />
intravenous administrati<strong>on</strong> (19, 34).<br />
Clinical pharmacology<br />
No informati<strong>on</strong> was found for single-entity preparati<strong>on</strong>s of Cortex<br />
Magnoliae.<br />
174